Treatment of infections due to resistant staphylococcus aureus

Methods in Molecular Biology

Volumn 1085, Issue , 2014, Pages 259-309

  Anstead, Gregory M ^a,b   Cadena, Jose ^a,b   Javeri, Heta ^b  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

ceftaroline; clindamycin; dalbavancin; daptomycin; delafloxacin; doxycycline; fosfomycin; fusidic acid; JNJ Q2; linezolid; minocycline; MRSA; omadacycline; oritavancin; pristinamycin; rifampin; telavancin; tidezolid; tigecycline; trimethoprim sulfamethoxazole; vancomycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AVAROFLOXACIN; AZTREONAM; BETA LACTAM; CEFAZOLIN; CEFTAROLINE; CEFTAROLINE FOSAMIL; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; GENTAMICIN; JNJ Q 2; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; NAFCILLIN; OMADACYCLINE; ORITAVANCIN; RIFAMPICIN; SULTAMICILLIN; TEDIZOLID; TEICOPLANIN; TELAVANCIN; TETRACYCLINE DERIVATIVE; TIGACYL; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ADD ON THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIUM ISOLATE; BONE INFECTION; CATHETER INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; CONTINUOUS INFUSION; COORDINATION DISORDER; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DEVICE INFECTION; DIABETIC FOOT; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; ENDOCARDITIS; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE INFECTION; HEALTH CARE ASSOCIATED PNEUMONIA; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; HYPERPYREXIA; HYPERREFLEXIA; INFECTIOUS ARTHRITIS; INSOMNIA; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LOADING DRUG DOSE; MENINGITIS; MENTAL HEALTH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; MYOCARDITIS; MYOCLONUS; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OPTIMAL DRUG DOSE; OSTEOMYELITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROSTHETIC VALVE ENDOCARDITIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; SEROTONIN SYNDROME; SHIVERING; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREMOR; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 84934441160     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-664-1_16     Document Type: Article

References (205)

1. Liu C, Bayer A, Cosgrove SE et al (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18-e55
2. Lindsay JA, Holden MTG (2004) Staphylococcus aureus : superbug, super genome? Trends Microbiol 12:378-385
3. Naimi TS, LeDell KH, Como-Sabetti K et al (2003) Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290: 2976-2984
4. Rybak MJ, LaPlante KL (2005) Communityassociated methicillin-resistant Staphylococcus aureus : a review. Pharmacotherapy 25: 74-85
5. Skov RL, Jensen KS (2009) Communityassociated methicillin-resistant Staphylococcus aureus as a cause of hospital-acquired infections. J Hosp Infect 73:364-370
6. de Kraker ME, Wolkewitz M, Davey PG et al (2011) Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 55:1598-1605
7. Klevens RM, Morrison MA, Nadle J (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771
8. Gould IM, David MZ, Esposito S et al (2012) New insights into methicillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 39:96-104
9. Kallen AJ, Mu Y, Bulens S et al (2010) Health care-associated invasive MRSA infections, 2005-2008. JAMA 304:641-648
10. Landrum ML, Neumann C, Cook C et al (2012) Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA 308:50-59
11. Calfee DP, Salgado CD, Classen D et al (2008) Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol 29(Suppl 1):S62-S80
12. Tenover FC, Moellering RC Jr (2007) The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus . Clin Infect Dis 44:1208-1215
13. Gould IM (2010) VRSA-doomsday superbug or damp squib? Lancet Infect Dis 10:816-818
14. Saravolatz LD, Pawlak J, Johnson LB (2012) In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycinresistant Staphylococcus aureus isolates. Clin Infect Dis 55:582-586
15. Siberry GK, Tekle T, Carroll K, Dick J (2003) Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 37:1257-1260
16. Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH (2003) Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol 41:4740-4744
17. Como-Sabetti K, Harriman KH, Buck JM et al (2009) Community-associated methicillin-resistant Staphylococcus aureus : trends in case and isolate characteristics from six years of prospective surveillance. Public Health Rep 124:427-435
18. Levine DP (2006) Vancomycin: a history. Clin Infect Dis 42:S5-S12
19. Kollef MH, Micek ST (2005) Staphylococcus aureus pneumonia. A "superbug" infection in community and hospital settings. Chest 128:1093-1096
20. Stevens DL (2006) The role of vancomycin in the treatment paradigm. Clin Infect Dis 42:S51-S57
21. Stryjewski ME, Szczech LA, Benjamin DK Jr et al (2007) Use of vancomycin or fi rstgeneration cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 44:190-196
22. Rello J, Torres A, Ricart M et al (1994) Ventilator-associated pneumonia by Staphylococcus aureus . Comparison of methicillin-sensitive and methicillin-resistant episodes. Am J Respir Crit Care Med 150:1545-1549
23. Tice AD, Hoagland P, Shoultz DA (2003) Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 114:723-728
24. Chambers HF (1997) Parenteral antibiotics for the treatment of bacteremia and other serious staphylococcal infections. In: Crossley KB, Archer GL (eds) The staphylococci in human disease. Churchill-Livingstone, New York, pp 583-601
25. Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T (2011) Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int J Antimicrob Agents 37:219-224
26. Sader HS, Fey PD, Limaye AP et al (2009) Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 53:4127-4132
27. van Hal SJ, Lodise TP, Paterson DL (2012) The clinical signifi cance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 54:755-771
28. Brink A (2012) Does resistance in severe infections caused by methicillin-resistant Staphylococcus aureus give you the 'creeps'? Curr Opin Crit Care 18:451-459
29. Rybak M, Lomaestro B, Rotschafer JC et al (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82-98
30. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N (2012) Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 67:17-24
31. Vandecasteele SJ, De Vriese AS, Tacconelli E (2013) The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. J Antimicrob Chemother 68(4):743-748
32. Wysocki M, Delatour F, Faurisson F et al (2001) Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 45:2460-2467
33. Jeffres MN, Isakow W, Doherty JA et al (2006) Predictors of mortality for methicillinresistant Staphylococcus aureus health-careassociated pneumonia: specifi c evaluation of vancomycin pharmacokinetic indices. Chest 130:947-955
34. Itani KM, Dryden MS, Bhattacharyya H et al (2010) Effi cacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus . Am J Surg 199:804-816
35. Patel N, Pai MP, Rodvold KA et al (2011) Vancomycin: we can't get there from here. Clin Infect Dis 52:969-974
36. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: effi cacy and toxicity. Arch Intern Med 166:2138-2144
37. Watkins RR, Lemonovich TL, File TM Jr (2012) An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy. Core Evid 7:131-143
38. Wunderink RG, Bello J, Cammarata SK, Croos-Dadrera RV, Kollef MH (2003) Linezolid vs vancomycin. Analysis of two double-blind studies of patients with methicillinresistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789-1797
39. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG (2004) Clinical cure and survival in Gram-positive ventilatorassociated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30:388-394
40. Ioanas M, Lode H (2004) Linezolid in VAP by MRSA: better choice? Intensive Care Med 30:343-346
41. Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R (2003) Intrapulmonary penetration of linezolid. J Antimicrob Chemother 51:1431-1434
42. Alaniz C, Pogue JM (2012) Vancomycin versus linezolid in the treatment of methicillinresistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial. Ann Pharmacother 46:1432-1435
43. Wunderink RG, Niederman MS, Kollef MH et al (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized controlled trial. Clin Infect Dis 54:621-629
44. Micek ST, Dunne M, Kollef MH (2005) Pleuropulmonary complications of Panton-Valentine leukocidin-positive communityacquired methicillin-resistant Staphylococcus aureus : importance of treatment with antimicrobials inhibiting exotoxin production. Chest 128:2732-2738
45. Shukla SK (2005) Community-associated methicillin-resistant Staphylococcus aureus and its emerging virulence. Clin Med Res 3: 57-60
46. Bernardo K, Pakulat N, Fleer S et al (2004) Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 48:544-546
47. Lewis JS II, Jorgensen JH (2005) Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis 40:280-285
48. Weigelt J, Kaafarani HMA, Itani KMF, Swanson RN (2004) Linezolid eradicates MRSA better than vancomycin from surgicalsite infections. Am J Surg 188:760-766
49. Weigelt J, Itani K, Stevens D et al (2005) Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49: 2260-2266
50. Sharpe JN, Shively MD, Polk HC Jr (2005) Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lowerextremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus . Am J Surg 189:425-428
51. Duane TM, Weigelt JA, Puzniak LA, Huang DB (2012) Linezolid and vancomycin in treatment of lower-extremity complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus in patients with and without vascular disease. Surg Infect (Larchmt) 13:147-153
52. Lipsky BA, Itani K, Norden C (2004) Linezolid Diabetic Foot Infection Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, openlabel trial of linezolid versus ampicillinsulbactam/ amoxicillin-clavulanate. Clin Infect Dis 38:17-24
53. Rayner CR, Baddour LM, Birmingham MC et al (2004) Linezolid in the treatment of osteomyelitis: results of a compassionate use experience. Infection 32:8-14
54. Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ (2007) Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 29:233-239
55. Kutscha-Lissberg F, Hebler U, Muhr G, Koller M (2003) Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 47:3964-3966
56. Shorr AF, Kunkek MJ, Kollef M (2005) Linezolid versus vancomycin for Staphylococcus aureus bacteraemia; pooled analysis of randomized studies. J Antimicrob Chemother 56:923-929
57. Park HJ, Kim SH, Kim MJ et al (2012) Effi cacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J Infect 65:505-512
58. Wilcox MH, Tack KJ, Bouza E et al (2009) Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 48:203-212
59. Lauridsen TK, Bruun LE, Rasmussen RV et al (2012) Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study. Eur J Clin Microbiol Infect Dis 31:2567-2574
60. Tascini C, Bongiorni MG, Doria R et al (2011) Linezolid for endocarditis: a case series of 14 patients. J Antimicrob Chemother 66:679-682
61. Kessler AT, Kourtis AP (2007) Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid. Infection 35:271-274
62. Naesens R, Ronsyn M, Druwé P et al (2009) Central nervous system invasion by community-acquired meticillin-resistant Staphylococcus aureus . J Med Microbiol 58:1247-1251
63. Sipahi OR, Bardak S, Turhan T et al (2011) Linezolid in the treatment of methicillinresistant staphylococcal post-neurosurgical meningitis: a series of 17 cases. Scand J Infect Dis 43:757-764
64. Howden BP, Charles PGP, Johnson PDR, Ward PB, Grayson ML (2005) Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections; better drug or reduced vancomycin susceptibility? Antimicrob Agents Chemother 49:4816-4817
65. Soriano A, Marco F, Martinez JA et al (2008) Infl uence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis 46:193-200
66. Lodise TP, Graves J, Evans A et al (2008) Relationship between vancomycin MIC and failure among patients with methicillin resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52:3315-3320
67. Choi EY, Huh JW, Lim C et al (2011) Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med 37:639-647
68. Haque NZ, Zuniga LC, Peyrani P et al (2010) Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care associated pneumonia. Chest 138:1356-1362
69. Sancak B, Ercis S, Menemenlioglu D, Çolakoglu S, Hasçelik G (2005) Methicillinresistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 56:519-523
70. Krause KM, Blais J, Lewis SR et al (2012) In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 74:429-431
71. Deresinski S (2007) Counterpoint: vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 44: 1543-1548
72. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML (2004) Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus . Clin Infect Dis 38:448-451
73. Khatib R, Jose J, Musta A et al (2011) Relevance of vancomycin- intermediate susceptibility and heteroresistance in methicillinresistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 66:1594-1599
74. Satola SW, Lessa FC, Ray SM et al (2011) Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. aureus phenotype. J Clin Microbiol 49:1583-1587
75. van Hal SJ, Jones M, Gosbell IB, Paterson DL (2011) Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. PLoS One 6:e21217
76. Nasraway SA, Shorr AF, Kuter DJ et al (2003) Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 37:1609-1616
77. Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL (2004) Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic devices. Clin Infect Dis 38:1058-1064
78. Radunz S, Juntermanns B, Kaiser GM et al (2011) Effi cacy and safety of linezolid in liver transplant patients. Transpl Infect Dis 13: 353-358
79. Jaksic B, Martinelli G, Perez-Oteyza J et al (2006) Effi cacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42: 597-607
80. Bergeron L, Boulé M, Perreault S (2005) Serotonin toxicity associated with concomitant use of linezolid. Ann Pharmacother 39:956-961
81. Butterfi eld JM, Lawrence KR, Reisman A et al (2012) Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data. J Antimicrob Chemother 67:494-502
82. Anonymous (2004) Pfi zer: Zyvox (linezolid). Safety-nervous-psychiatric. Reports of peripheral or optic neuropathy. Data on fi le
83. Birmingham MC, Rayner CR, Meagher AK et al (2003) Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36:159-168
84. Frippiat F, Bergiers C, Michel C, Dujardin JP, Derue G (2004) Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 53:114-115
85. Ferry T, Ponceau B, Simon M et al (2005) Possibly linezolid-induced peripheral and central nervous system neurotoxicity: report of four cases. Infection 33:151-154
86. US Food and Drug Administration (2013) Highlights of prescribing information-Zyvox. www.accessdata.fda.gov/drugsatfdadocs/-label/2008/021130s016, 021131s013,0211 32s014lbl.pdf . Accessed 25 Jan 2013
87. Lomaestro BM (2003) Resistance to linezolid. Are we surprised? How hard should we look? Ann Pharmacother 37:909-911
88. Mendes RE, Sader HS, Farrell DJ, Jones RN (2012) Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals (2007-2009). Diagn Microbiol Infect Dis 72:113-117
89. Morales G, Picazo JJ, Baos E et al (2010) Resistance to linezolid is mediated by the cfr gene in the fi rst report of an outbreak of linezolid-resistant Staphylococcus aureus . Clin Infect Dis 50:821-825
90. Pea F, Furlanut M, Cojutti P et al (2010) Therapeutic drug monitoring of linezolid: a retrospective, monocentric analysis. Antimicrob Agents Chemother 54:4605-4610
91. Fenton C, Keating GM, Curran MP (2004) Daptomycin. Drugs 64:445-455
92. Arbeit RD, Maki D, Tally FP et al (2004) The safety and effi cacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38:1673-1681
93. Fowler VG Jr, Boucher HW, Corey GR et al (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus . N Engl J Med 355: 653-665
94. Moore CL, Osaki-Kiyan P, Haque NZ et al (2012) Daptomycin versus vancomycin for bloodstream infections due to methicillinresistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 54:51-58
95. Jobson S, Moise PA, Eskandarian R (2011) Retrospective observational study comparing vancomycin versus daptomycin as initial therapy for Staphylococcus aureus infections. Clin Ther 33:1391-1399
96. Moenster RP, Linneman TW, Finnegan PM, McDonald JR (2012) Daptomycin compared to vancomycin for the treatment of osteomyelitis: a single-center, retrospective cohort study. Clin Ther 34:1521-1527
97. Gallagher JC, Huntington JA, Culshaw D et al (2012) Daptomycin therapy for osteomyelitis: a retrospective study. BMC Infect Dis 12:133
98. Parra-Ruiz J, Vidaillac C, Rose WE et al (2010) Activities of high-dose daptomycin, vancomycin, and moxifl oxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofi lm. Antimicrob Agents Chemother 54:4329-4334
99. Echevarria K, Datta P, Cadena J, Lewis JS II (2005) Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 55:599-600
100. Golightly LK, Barber GR, Barron MA, Page RL II (2013) Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Drug Metabol Drug Interact 9:1-10
101. White B, Seaton RA (2011) Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin. Infect Drug Resist 4:115-127
102. Durante-Mangoni E, Casillo R, Bernardo M et al (2012) High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin Infect Dis 54:347-354
103. Kullar R, Davis SL, Levine DP et al (2011) High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 31:527-536
104. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT (2003) Effi cacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 47:1714-1718
105. Tsuji BT, Rybak MJ (2005) Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 49:2735-2745
106. Steed ME, Werth BJ, Ireland CE, Rybak MJ (2012) Evaluation of the novel combination of high-dose daptomycin plus trimethoprimsulfamethoxazole against daptomycinnonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother 56:5709-5714
107. Mehta S, Singh C, Plata KB et al (2012) ?-Lactams increase the antibacterial activity of daptomycin against clinical methicillinresistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 56:6192-6200
108. Rose WE, Schulz LT, Andes D et al (2012) Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 56:5296-5302
109. Dhand A, Bayer AS, Pogliano J et al (2011) Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillinresistant Staphylococcus aureus : role of enhanced daptomycin binding. Clin Infect Dis 53:158-163
110. Steenbergen JN, Mohr JF, Thorne GM (2009) Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother 64:1130-1138
111. van Hal SJ, Paterson DL, Gosbell IB (2011) Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient-a review of the literature. Eur J Clin Microbiol Infect Dis 30:603-610
112. Yang SJ, Xiong YQ, Boyle-Vavra S et al (2010) Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother 54:3169-3179
113. Klastersky J (2003) Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients. Cancer Treat Rev 29:431-440
114. Guignard B, Vouillamoz J, Giddey M, Moreillon P (2013) A positive interaction between inhibitors of protein synthesis and cefepime in the fi ght against methicillinresistant Staphylococcus aureus . Eur J Clin Microbiol Infect Dis 32(7):899-907
115. Bhattacharya M, Parakh A, Narang MJ (2009) Tigecycline. Postgrad Med 55:65-68
116. European Medicines Agency (EMA) (2011) Questions and answers on the review of Tygacil (tigecycline). Outcome of a renewal procedure EMA, London, UK. [EMA/121925/2011] http://www.ema. europa.eu/docs/en-GB/document-library/M e d i c i n e-Q A/h u m a n/0 0 0 6 4 4/WC500102228.pdf . Accessed 21 Jul 2011
117. Pfi zer (2011) Direct healthcare professional communication on increase in mortality in clinical trials of Tygacil ® (tigecycline)
118. Cai Y, Wang R, Liang B, Bai N, Liu Y (2011) Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious diseases. Antimicrob Agents Chemother 55:1162-1172
119. Ambrose PG, Meagher AK, Passarell JA et al (2009) Application of patient populationderived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn Microbiol Infect Dis 63:155-159
120. Chong YP, Park SJ, Kim HS et al (2012) In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratifi ed analysis by vancomycin MIC. Diagn Microbiol Infect Dis 73:264-266
121. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ (2005) The pharmacokinetic and pharmacodynamic profi le of tigecycline. Clin Infect Dis 41(Suppl 5):S333-S340
122. Chang MH, Kish TD, Fung HB (2010) Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults. Clin Ther 32:2160-2185
123. Stryjewski ME, Graham DR, Wilson SE et al (2008) Telavancin versus vancomycin for the treatment of complicated skin and skinstructure infections caused by gram-positive organisms. Clin Infect Dis 46:1683-1693
124. Nannini EC, Corey GR, Stryjewski ME (2012) Telavancin for the treatment of hospital-acquired pneumonia: fi ndings from the ATTAIN studies. Expert Rev Anti Infect Ther 10:847-854
125. Polyzos KA, Mavros MN, Vardakas KZ et al (2012) Effi cacy and safety of telavancin in clinical trials: a systematic review and metaanalysis. PLoS One 7:e41870
126. Theravance Inc. (2011) Important update regarding the availability of VIBATIV ® (telavancin for injection). http://fi les.shareh o l d e r. c o m/d o w n l o a d s/T H E R A/0x0xS1104659-1164687/1080014/fi ling. pdf . Accessed 2 Jan 2013.
127. File TM Jr, Wilcox MH, Stein GE (2012) Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 55(Suppl 3):S173-S180
128. Steed M, Vidaillac C, Rybak MJ (2011) Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillinresistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 55:3522-3526
129. Wilcox MH, Corey GR, Talbot GH (2010) CANVAS 2: the second phase III, randomized double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65:53-65
130. Corey GR, Wilcox MH, Talbot GH (2010) CANVAS 1: the fi rst phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65(Suppl 4):S41-S51
131. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS II (2012) Methicillinresistant S taphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 67:1267-1270
132. Zhanel GG, Sniezek G, Schweizer F et al (2009) Ceftaroline: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus . Drugs 69:809-831
133. Jacqueline C, Caillon J, Le Mabecque V et al (2009) In vivo activity of a novel antimethicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and-resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin. Antimicrob Agents Chemother 53:5300-5302
134. Jacqueline C, Caillon J, Le Mabecque V et al (2007) In vivo effi cacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycinintermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 51:3397-3400
135. Jacqueline C, Amador G, Caillon J et al (2010) Effi cacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother 65:1749-1752
136. Lin JC, Aung G, Thomas A et al (2013) The use of ceftaroline fosamil in methicillinresistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 19(1):42-49
137. McCollum M, Rhew DC, Parodi S (2003) Cost analysis of switching from IV vancomycin to po linezolid for the management of methicillin-resistant Staphylococcus species. Clin Ther 25:3173-3189
138. Itani KMF, Weigelt J, Li JZ, Duttagupta S (2005) Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus . Int J Antimicrob Agents 26:442-448
139. Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R et al (2012) Risk factors for Clostridium diffi cile toxin-positive diarrhea: a population-based prospective case-control study. Eur J Clin Microbiol Infect Dis 31:2601-2610
140. Yuk JH, Dignani MC, Harris RL, Bradshaw MW, Williams TW Jr (1991) Minocycline as an alternative antistaphylococcal agent. Rev Infect Dis 13:1023-1024
141. Ruhe JJ, Menon A (2007) Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 51:3298-3303
142. Nicolau DP, Freeman CD, Nightingale CH, Coe CJ, Quintiliani R (1994) Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillinresistant Staphylococcus aureus . Antimicrob Agents Chemother 38:1515-1518
143. Cunha BA (2010) Minocycline versus doxycycline for meticillin-resistant Staphylococcus aureus (MRSA): in vitro susceptibility versus in vivo effectiveness. Int J Antimicrob Agents 35:517-518
144. Draghi DC, Sheehan DJ, Hogan P, Sahm DF (2005) In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 Surveillance Program. Antimicrob Agents Chemother 49:5024-5032
145. Hasty MB, Klasner A, Kness S (2007) Cutaneous community-associated methicillinresistant Staphylococcus aureus among all skin and soft-tissue infections in two geographically distant pediatric emergency departments. Acad Emerg Med 14:35-40
146. Moran GJ, Krishnadasan A, Gorwitz RJ et al (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666-674
147. Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG (2008) Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 168:805-819
148. Dailey CF, Pagano PJ, Buchanan LV et al (2003) Effi cacy of linezolid plus rifampin in an experimental model of methicillinsusceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 47: 2655-2658
149. Miró JM, García-de-la-Mària C, Armero Y et al (2009) Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin- resistant Staphylococcus aureus . Antimicrob Agents Chemother 53:4172-4177
150. Egle H, Trittler R, Kummerer K, Lemmen SW (2005) Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 77:451-453
151. Jung YJ, Koh Y, Hong SB et al (2010) Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 38:175-180
152. Ramsey KM, Mazer MA (2010) Addition of rifampin to vancomycin for the treatment of pneumonias due to methicillin-resistant Staphylococcus aureus : caveat emptor. Crit Care Med 38:326-327
153. Lefebvre M, Jacqueline C, Amador G et al (2010) Effi cacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int J Antimicrob Agents 36:542-544
154. Nguyen S, Pasquet A, Legout L et al (2009) Effi cacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 15:1163-1169
155. Daver NG, Shelburne SA, Atmar RL et al (2007) Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect 54:539-544
156. Garrigós C, Murillo O, Euba G et al (2010) Effi cacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 54:5251-5256
157. John AK, Baldoni D, Haschke M et al (2009) Effi cacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus : importance of combination with rifampin. Antimicrob Agents Chemother 53:2719-2724
158. Garrigós C, Murillo O, Lora-Tamayo J et al (2013) Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 57:606-610
159. Zimmerli W, Moser C (2012) Pathogenesis and treatment concepts of orthopaedic biofi lm infections. FEMS Immunol Med Microbiol 65:158-168
160. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE (1998) Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279:1537-1541
161. Shopsin B, Zhao X, Kreiswirth BN, Tillotson GS, Drlica K (2004) Are the new quinolones appropriate treatment for community-acquired methicillin- resistant Staphylococcus aureus ? Internat J Antimicrob Agents 24:32-34
162. San JR, Garcia-Reyne A, Caba P et al (2010) Safety and effi cacy of moxifl oxacin monotherapy for treatment of treatment of orthopedic implant-related staphylococcal infections. Antimicrob Agents Chemother 54:5161-5166
163. Shittu A, Oyedara O, Abegunrin F et al (2102) Characterization of methicillinsusceptible and-resistant staphylococci in the clinical setting: a multicentre study in Nigeria. BMC Infect Dis 12:286
164. Ellis MW, Lewis JS II (2005) Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus . Curr Opin Infect Dis 18:496-501
165. Markowitz N, Quinn EL, Saravolatz LD (1992) Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment for the treatment of Staphylococcus aureus infection. Ann Intern Med 117:390-398
166. de Górgolas M, Avilés P, Vedejo C, Fernandez Guerrero ML (1995) Treatment of experimental endocarditis due to methicillinsusceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob Agents Chemother 39:953-957
167. Cadena J, Nair S, Henao-Martinez AF et al (2011) Dose of trimethoprimsulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 55:5430-5432
168. Frei CR, Miller ML, Lewis JS II et al (2010) Trimethoprim- sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med 23:714-719
169. Campbell ML, Marchaim D, Pogue JM et al (2012) Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 ?g/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Ann Pharmacother 46:1587-1597
170. Stein A, Bataille JF, Drancourt M et al (1998) Ambulatory treatment of multi-drug resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole ( trimethoprim-sulfamethoxazole) . Antimicrob Agents Chemother 42:3086-3091
171. Johnson JR (2003) Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 36:236-237
172. Iyer S, Jones DH (2004) Communityacquired methicillin-resistant skin infections: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 50:854-858
173. Howden BP, Grayson ML (2006) Dumb and dumber-the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus . Clin Infect Dis 42:394-400
174. Wang JL, Tang HJ, Hsieh PH et al (2012) Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus . Int J Antimicrob Agents 40:103-107
175. Katopodis GD, Grivea IN, Tsantsaridou AJ et al (2010) Fusidic acid and clindamycin resistance in community-associated, methicillin-resistant Staphylococcus aureus infections in children of Central Greece. BMC Infect Dis 10:351
176. Pfaller MA, Castanheira M, Sader HS, Jones RN (2010) Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. Int J Antimicrob Agents 35:282-287
177. Peel TN, Buising KL, Dowsey MM et al (2013) Outcome of debridement and retention in prosthetic joint infections by methicillin-resistant staphylococci, with special reference to rifampin and fusidic acid combination therapy. Antimicrob Agents Chemother 57:350-355
178. Fernandes P, Pereira D (2011) Efforts to support the development of fusidic acid in the United States. Clin Infect Dis 52(Suppl 7): S542-S546
179. Craft JC, Moriarty SR, Clark K et al (2011) A randomized, double-blind phase 2 study comparing the effi cacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis 52(Suppl 7):S520-S526
180. Rayner C, Munckhof WJ (2005) Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus . Intern Med J 35(Suppl 2):S3-S16
181. Lamy B, Laurent F, Gallon O et al (2012) Antibacterial resistance, genes encoding toxins and genetic background among Staphylococcus aureus isolated from community-acquired skin and soft tissue infections in France: a national prospective survey. Eur J Clin Microbiol Infect Dis 31:1279-1284
182. Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F (2001) In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 48:209-217
183. Hamilton-Miller JM (1992) In vitro activity of fosfomycin against 'problem' gram-positive cocci. Microbios 71:95-103
184. Poeppl W, Tobudic S, Lingscheid T et al (2011) Effi cacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 55:931-933
185. Schintler MV, Traunmüller F, Metzler J et al (2009) High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother 64:574-578
186. McCaughey G, McKevitt M, Elborn JS, Tunney MM (2012) Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fi brosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros 11:63-72
187. Lee MC, Rios AM, Aten MF et al (2004) Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus . Pediatr Infect Dis J 23:123-127
188. Zhanel GG, Schweizer F, Karlowsky JA (2012) Oritavancin: mechanism of action. Clin Infect Dis 54(Suppl 3):S214-S219
189. Giamarellou H, O'Riordan W, Harris H et al (2003) Phase 3 trial comparing 3-7 days of oritavancin vs. 10-14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSSI) [abstract L-739a]. In: Program and abstracts of the 43rd interscience conference of antimicrobial agents and chemotherapy (Chicago, IL). American Society for Microbiology, Washington, DC
190. Wasilewski M, Disch D, McGill J et al (2001) Equivalence of shorter course therapy with oritavancin vs. vancomycin/cephalexin in complicated skin-skin structure infections (cSSSI) [abstract UL-18]. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy (Chicago, IL). American Society for Microbiology, Washington, DC
191. Arias CA, Mendes RE, Stilwell MG, Jones RN, Murray BE (2012) Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. Clin Infect Dis 54(Suppl 3): S233-S238
192. Loutit JS, O'Riordan W, San Juan J et al (2004) Phase 2 trial comparing four regimens of oritavancin vs. comparator in the treatment of patients with S. aureus bacteremia. Clin Microbiol Infect 10(Suppl 3):S122
193. Tice A (2012) Oritavancin: a new opportunity for outpatient therapy of serious infections. Clin Infect Dis 54(Suppl 3):S239-S243
194. Dunbar LM, Milata J, McClure T, Wasilewski MM, SIMPLIFI Study Team (2011) Comparison of the effi cacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother 55:3476-3484
195. Zhanel GG, Calic D, Schweizer F et al (2010) New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70:859-886
196. Jauregui LE, Babazadeh S, Seltzer E et al (2005) Randomized, double-blind comparison of once-weekly dalbavancin versus twicedaily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41:1407-1415
197. Gould IM, Bal AM (2013) New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence 4(2):185-191
198. Prokocimer PP, Bien P, Deanda C, Pillar CM, Bartizal K (2012) In vitro activity and microbiological effi cacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 56:4608-4613
199. Lemaire S, Kosowska-Shick K, Appelbaum PC et al (2010) Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and non-phagocytic cells, using Staphylococcus aureus , Staphylococcus epidermidis , Listeria monocytogenes , and Legionella pneumophila . Antimicrob Agents Chemother 54:2549-2559
200. Lemaire S, Tulkens PM, Van Bambeke F (2011) Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fl uoroquinolones moxifl oxacin and delafl oxacin against Staphylococcus aureus . Antimicrob Agents Chemother 55:649-658
201. Covington P, Davenport JM, Andrae D et al (2011) Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and effi cacy of JNJ-Q2, a novel fl uoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob Agents Chemother 55:5790-5797
202. Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit RD (2012) A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 56:5650-5654
203. Vidaillac C, Parra-Ruiz J, Winterfi eld P, Rybak MJ (2011) In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates. Int J Antimicrob Agents 38:301-306
204. Osborne CS, Neckermann G, Fischer E et al (2009) In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. Antimicrob Agents Chemother 53:3777-3781
205. Vardakas KZ, Mavros MN, Roussos N, Falagas ME (2012) Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. Mayo Clin Proc 87:349-363